Carfilzomib-induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective study-Reference-Cited by-同舟云学术

Carfilzomib-induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective study

Published:2021-02-15 Issue:5 Volume:35 Page:1418-1427
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Kastritis Efstathios^ORCID,Laina Ageliki,Georgiopoulos Georgios,Gavriatopoulou Maria^ORCID,Papanagnou Eleni-Dimitra,Eleutherakis-Papaiakovou Evangelos,Fotiou Despina,Kanellias Nikolaos,Dialoupi Ioanna,Makris Nikolaos,Manios Efstathios,Migkou Magdalini,Roussou Maria,Kotsopoulou Maria,Stellos Konstantinos,Terpos Evangelos^ORCID,Trougakos Ioannis P.,Stamatelopoulos Kimon,Dimopoulos Meletios A.

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-021-01141-4.pdf

Reference56 articles.

1. Ziogas DC, Terpos E, Kastritis E, Dimopoulos MA. An overview of the role of carfilzomib in the treatment of multiple myeloma. Expert Opin Pharmacother. 2017;18:1883–97.

2. Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2014;372:142–52.

3. Dimopoulos MA, Goldschmidt H, Niesvizky R, Joshua D, Chng WJ, Oriol A, et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol. 2017;18:1327–37.

4. Shah C, Bishnoi R, Jain A, Bejjanki H, Xiong S, Wang Y, et al. Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis. Leuk Lymphoma. 2018;59:2557–69.

5. Jain T, Narayanasamy H, Mikhael J, Reeder CB, Bergsagel PL, Mayo A, et al. Systolic dysfunction associated with carfilzomib use in patients with multiple myeloma. Blood Cancer J. 2017;7:642.

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Carfilzomib-induced thrombotic microangiopathy (TMA) refractory to eculizumab: A case report and literature review;Annals of Hematology;2024-08-27

2. Cancer Therapy and Exercise Intolerance: The Heart Is But a Part;JACC: CardioOncology;2024-08

3. The proteasome inhibitor carfilzomib exerts anti-inflammatory and antithrombotic effects on the endothelium;Journal of Thrombosis and Haemostasis;2024-07

4. Endothelial injury and dysfunction with emerging immunotherapies in multiple myeloma, the impact of COVID-19, and endothelial protection with a focus on the evolving role of defibrotide;Blood Reviews;2024-07

5. Clinical features, treatment, and outcomes of patients with carfilzomib induced thrombotic microangiopathy;International Immunopharmacology;2024-06